Press release

Jan 18, 2019

Hansa Medical Announces Appointment of Anne Säfström Lanner as Vice President, Global Human Resources

Lund, Sweden, January 18, 2019 -- Hansa Medical AB (NASDAQ Stockholm: HNSA), the leading biopharma company focusing on inhibition of immunoglobulin G (IgG)-mediated immunopathologies, today announced the appointment of Anne Säfström Lanner as Vice President, Global Human Resources.

Mrs. Lanner has over 15 years of broad human resources experience in international growth companies, including developing and implementing strategies for talent acquisition and management, organizational culture and employer branding, compensation and benefits, and employee training and development. Prior to joining Hansa, she served at European Spallation Source (ESS), a European multi-disciplinary research facility, in HR leadership roles of increasing responsibility, most recently as Head of Resourcing. Previously, Mrs. Lanner was Head of Human Resources at CellaVision, a provider of digital solutions for medical microscopy within hematology. She earned her Bachelor of Social Science in Human Resource Management, with a focus in organizational development & leadership, at Lund University.

“We are delighted to welcome Anne as we grow Hansa Medical into a global commercial-stage biopharma company. Anne is very experienced in developing strategic human resources programs aligned with business objectives and will work with management to help maximize Hansa’s organizational productivity and secure our position as an employer of choice,” said Søren Tulstrup, President & CEO of Hansa Medical.

The information was submitted for publication, through the agency of the contact person set out below at 08:00am CET on January 18, 2019. 

About Hansa Medical
Hansa Medical (NASDAQ Stockholm: HMED) is a biopharmaceutical company developing novel immunomodulatory enzymes for organ transplantation and acute autoimmune diseases. The Company’s lead product, imlifidase, is a proprietary antibody-degrading enzyme in late-stage clinical development for kidney transplant patients and has significant potential for further development in other solid organ transplantation and in acute autoimmune indications. Hansa also has a strong pipeline of preclinical projects that may provide a second wave of potential drugs. Under the project name NiceR, the Company is developing novel immunoglobulin-cleaving enzymes for repeat dosing in relapsing autoimmune diseases and oncology. Hansa Medical is based in Lund, Sweden.